As one of the countries eligible for HIV funding from the Global Fund, Malaysia can expect to gain access to lenacapavir through the health financing group. — AP Filepic
Low- and middle-income countries (LMICs) will gain access to a “game-changing” HIV prevention drug with a new deal signed between with US pharmaceutical giant Gilead and the Global Fund, the latter said on July 9 (2025).
The health financing group set up to battle AIDS, tuberculosis and malaria, described the deal to procure lenacapavir for LMICs (including Malaysia) as “a significant milestone for global health equity”.
